Cure8 research brief
The report suggests a probiotic (VSL#3TM) added to vedolizumab may speed or increase early response in ulcerative colitis, which could interest patients and clinicians seeking ways to improve biologic induction outcomes. However, evidence is preliminary and not definitive.
Adults with ulcerative colitis, clinicians prescribing vedolizumab, and researchers studying microbiome adjuncts to biologic therapy.
This is a retrospective, uncontrolled study of 17 patients treated at a single center in China who received VSL#3TM together with vedolizumab for at least 12 weeks. The authors report clinical response by PRO2 of 82% at week 6 and 100% at week 12, and clinical remission rates up to ~59% (PRO2) or 50% (Full Mayo) at week 12.
Quality-of-life scores (IBDQ) improved and no serious adverse events were reported. The study is limited by its small size, single-arm retrospective design, and reliance on historical comparisons rather than randomized controls; mechanisms (microbiota or immune effects) were not measured.
These results are hypothesis-generating and support the need for larger prospective randomized trials rather than immediate changes in clinical practice.
Preprint on medRxiv (not peer-reviewed); small retrospective single-arm study (n=17); no direct mechanistic testing; results need confirmation in larger randomized trials.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with UC on or starting vedolizumab may be interested because the study tests whether adding an oral CurQD supplement improves remission rates compared with vedolizumab alone. The trial could inform whether this...
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
ECCO 2026 presented multiple studies that could change IBD care across prevention, medical therapy (including pediatric data), complication‑directed strategies (perianal fistula), and technology‑assisted monitoring....
